Fibrogen reports first quarter 2023 financial results

• topline data from four phase 3 trials expected through 3q 2023 • completed non-dilutive term loan financing for up to $150 million with morgan stanley tactical value • entered into exclusive license for for46 with fortis therapeutics san francisco, may 08, 2023 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today reported financial results for the first quarter 2023 and provided an update on the company's recent developments. “we look forward to reporting topline data from four pivotal phase 3 trials through the third quarter of this year,” said enrique conterno, chief executive officer, fibrogen.
FGEN Ratings Summary
FGEN Quant Ranking